Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

CEL-SCI Corp

LSRM
Current price
0.64 EUR +0.011 EUR (+1.74%)
Last closed 0.7 USD
ISIN US1508376076
Sector Healthcare
Industry Biotechnology
Exchange Frankfurt Exchange
Capitalization 46 451 568 USD
Yield for 12 month -76.83 %
1Y
3Y
5Y
10Y
15Y
LSRM
21.11.2021 - 28.11.2021

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. Address: 8229 Boone Boulevard, Vienna, VA, United States, 22182

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.73 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-3 958 334 USD

Last Year

-3 883 386 USD

Current Quarter

-983 208 USD

Last Quarter

-988 762 USD

Key Figures LSRM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -25 523 336 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -61.41 %
PEG Ratio
Return On Equity TTM -250.2 %
Wall Street Target Price 7.73 USD
Revenue TTM 28 558 USD
Book Value 0.16 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -62.7 %
Dividend Yield
Gross Profit TTM -25 355 346 USD
Earnings per share -0.58 USD
Diluted Eps TTM -0.58 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics LSRM

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History LSRM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date 28.08.1996
Forward Annual Dividend Yield
Last Split Factor 1:25
Payout Ratio
Last Split Date 15.06.2017
Dividend Date 15.06.2017

Stock Valuation LSRM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM 11797.424
Enterprise Value EBITDA -3.7125
Price Book MRQ 5.4823

Financials LSRM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators LSRM

For 52 weeks

0.68 USD 3.23 USD
50 Day MA 1.01 USD
Shares Short Prior Month 4 423 873
200 Day MA 1.47 USD
Short Ratio 14.68
Shares Short 4 316 677
Short Percent 6.95 %